

Letter to the Editor

Temporary facial paralysis following a local lignocaine injection

Dipankar Hari Chakraborty¹

¹Skin Clinic, Aurora Skin Cancer Centre, Wangaratta, Australia.



***Corresponding author:**

Dipankar Hari Chakraborty,
Skin Clinic, Aurora Skin Cancer
Centre, Wangaratta, Australia.

chaks0367@gmail.com

Received: 31 July 2025

Accepted: 11 August 2025

Published: 11 October 2025

DOI

10.25259/CSDM_140_2025

Quick Response Code:



Dear Sir,

Local anesthetics such as lignocaine are widely used in dermatologic practice due to their rapid onset, effectiveness, and safety profile. Although adverse events are rare, transient facial nerve paralysis is an unusual but important complication that can cause considerable distress. We report a case of temporary facial nerve palsy following local lignocaine administration for a minor dermatologic procedure, with emphasis on anatomical considerations, clinical differentiation, and management. A middle-aged woman underwent elective removal of a benign mole on her left cheek. The procedure was performed under local anesthesia using 1 mL of 2% lignocaine with adrenaline. Injection was given subcutaneously with standard aseptic precautions. The excision was uneventful, and the patient was discharged with routine post-operative instructions. Approximately 4 h later, she returned with sudden-onset left facial weakness. Examination revealed lower motor neuron facial nerve palsy: inability to close the left eye fully, asymmetry of facial movements, and left oral commissure drooping. She was afebrile and neurologically intact, except for the facial weakness. A focused assessment excluded other cranial nerve involvement. Given the timing, small anesthetic volume, and site of injection, a diagnosis of transient facial nerve blockade due to anesthetic diffusion was made. The patient was reassured, and no pharmacologic intervention was necessary. Complete recovery occurred spontaneously within 12 h [Figure 1a-c].

The facial nerve (cranial nerve VII) exits the stylomastoid foramen and branches into temporal, zygomatic, buccal, mandibular, and cervical divisions. These innervate the muscles of facial expression and course superficially through the cheek and periauricular area. Injections in these regions^[1] risk unintended nerve blockade, especially with deeper or high-volume administration.^[2] Although this phenomenon is more often reported in dental or maxillofacial contexts, it may occur during dermatologic procedures involving the midface.^[3,4] Factors that influence risk include concentration and volume of anesthetic, depth of injection, and vasoconstrictive additives such as adrenaline that delay systemic absorption. It is critical to distinguish this reversible iatrogenic condition from other causes of facial paralysis, such as Bell's palsy, cerebrovascular accidents, or Ramsay Hunt syndrome. In this case, the absence of systemic signs, vesicular rash, or other neurological deficits, along with a clear temporal link to the procedure, supported a diagnosis of anesthetic-induced facial nerve palsy.^[5] Imaging or further investigations are generally unnecessary if the presentation is classic and recovery is swift.

Management is conservative. Patients should be reassured that this is a self-limiting condition with expected full recovery. Nonetheless, clinicians must be aware of this possibility and take

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

©2025 Published by Scientific Scholar on behalf of CosmoDerma




Figure 1: (a and b) Four hours after surgery, (c) 12 hours after surgery.

steps to minimize risk. This includes using minimal effective anesthetic volume, injecting slowly, and avoiding deep injections in known danger zones—especially near the parotid gland, zygomatic arch, and mandibular angle. It is also advisable to inform patients undergoing facial procedures of this rare risk during pre-operative counseling. This case reinforces the importance of anatomical knowledge, careful injection technique, and calm clinical judgment when faced with unexpected post-operative facial weakness. Raising awareness of this benign complication can help reduce unnecessary referrals and alleviate both patient and practitioner anxiety.

Acknowledgment: The author would like to thank the patient for consenting to use of clinical details and images. No funding was received, and there are no conflicts of interest to declare.

Ethical approval: Institutional Review Board approval is not required.

Declaration of patient consent: The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship: Nil.

Conflicts of interest: There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation: The author confirms that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript, and no images were manipulated using AI.

REFERENCES

1. Moore KL, Dalley AF, Agur AM. Clinically oriented anatomy. 7th ed. Philadelphia, PA: Wolters Kluwer; 2013. p. 812-4.
2. Gaffen AS, Haas DA. Retrospective review of transient facial nerve paralysis following dental local anesthesia. *J Can Dent Assoc* 2009;75:531-4.
3. Scully C. Scully's oral and maxillofacial medicine. 4th ed. Edinburgh: Elsevier; 2016. p. 347-70.
4. Prasanna LC, Karki M, Suresh R, Kalthur SG, Souza AS, Pai MM, *et al.* Distribution and clinical significance of the facial nerve and its branches: A cadaveric study. *Clin Anat* 2012;25:632-40.
5. Kim JH, Ahn DK. Transient facial nerve paralysis following parotid gland surgery: A review. *J Korean Assoc Oral Maxillofac Surg* 2014;40:1-7.

How to cite this article: Chakraborty DH. Temporary facial paralysis following a local lignocaine injection. *CosmoDerma*. 2025;5:112. doi: 10.25259/CSDM_140_2025